Orbit Entered into a Multi Target Research Agreement with Endevica Bio to Advance Development of Cachexia Therapies
Shots:
- Orbit & Endevica Bio collaborated to advance the development of cachexia therapies caused by cancer & other chronic conditions. By using Endevica's technology platform, peptides can be altered to modify the activity of GPCRs behind the blood-brain barrier
- The collaboration helps to advance Endevica’s development of GPCR-targeting therapies on receptor sets to its lead compound. The agreement combines Orbit’s peptide discovery capabilities & Endevica Bio’s expertise in drug development to facilitate the accelerated entry of complimentary therapeutics portfolios into the clinic
- The agreement's main goal is to find peptide hits from particular library populations using internal in silico & modeling tools directly applied to Orbit's functional screening platform to find protein agonism
Ref: Businesswire | Image: Orbit
Related News:- Cardiovascular Systems, Inc. Reports the First Patient Enrollment of Diamondback 360 Peripheral Orbital Atherectomy System in Japan
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
